Bridgeway Capital Management LLC Sells 233,200 Shares of Inogen, Inc $INGN

Key Points

• Bridgeway Capital Management LLC reduced its stake in Inogen, Inc by 36.9%, holding 398,030 shares worth approximately $2.84 million at the end of the reporting period.
• Several other institutional investors have increased their holdings in Inogen, with DAFNA Capital Management raising its stake by 119.4% to own 458,065 shares worth about $3.27 million.
• Despite recent fluctuations, Inogen has received a "Moderate Buy" rating from analysts, with a price target of $11.00, while the stock is currently valued at around $8.11.

Bridgeway Capital Management LLC lowered its position in Inogen, Inc (NASDAQ:INGN - Free Report) by 36.9% during the first quarter, according to its most recent filing with the SEC. The firm owned 398,030 shares of the medical technology company's stock after selling 233,200 shares during the period. Bridgeway Capital Management LLC owned 1.48% of Inogen worth $2,838,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Inogen in the 1st quarter valued at $99,000. GAMMA Investing LLC increased its stake in shares of Inogen by 5,738.9% in the 1st quarter. GAMMA Investing LLC now owns 5,547 shares of the medical technology company's stock valued at $400,000 after acquiring an additional 5,452 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Inogen by 2.7% in the 4th quarter. Bank of America Corp DE now owns 127,326 shares of the medical technology company's stock valued at $1,168,000 after acquiring an additional 3,304 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Inogen by 25.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 607,837 shares of the medical technology company's stock valued at $5,574,000 after purchasing an additional 123,208 shares in the last quarter. Finally, CWM LLC increased its stake in Inogen by 71.7% during the 1st quarter. CWM LLC now owns 14,647 shares of the medical technology company's stock valued at $104,000 after purchasing an additional 6,118 shares in the last quarter. Institutional investors and hedge funds own 89.94% of the company's stock.

Inogen Trading Down 2.5%

Inogen stock traded down $0.21 on Wednesday, hitting $8.32. 172,729 shares of the stock traded hands, compared to its average volume of 273,573. Inogen, Inc has a 1 year low of $5.70 and a 1 year high of $12.91. The business's fifty day simple moving average is $7.20 and its 200 day simple moving average is $7.08. The firm has a market cap of $224.97 million, a P/E ratio of -7.85 and a beta of 1.78.

Inogen (NASDAQ:INGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical technology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.07. Inogen had a negative return on equity of 13.77% and a negative net margin of 7.58%.The firm had revenue of $92.28 million during the quarter, compared to the consensus estimate of $90.40 million. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts predict that Inogen, Inc will post -1.73 earnings per share for the current year.

Analyst Ratings Changes

INGN has been the topic of a number of research analyst reports. Needham & Company LLC raised shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price target on the stock in a report on Thursday, May 22nd. B. Riley began coverage on shares of Inogen in a report on Monday, June 16th. They issued a "buy" rating and a $14.00 price target for the company. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $11.00.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.